Scientific Blogs

The latest developments of Medis QFR®

November 2022 edition

Written by Prof. Hans Reiber on November 17, 2022

Given the regular posts of peer-reviewed scientific publications on the Medis QFR ®, it is clear that this angio-based solution for coronary physiology is extensively used in clinical research and practice. We would like to share these publications with you. So that you remain up to date about the research that is ongoing worldwide with this innovative solution, whereby each time new clinical applications are being tested, validated and tried out in particular populations. With its non-invasive nature, readily available, and broad applicability, we anticipate significant growth in its usage. This growth is supported by our constant quest for further automation.

In this new Medis QFR ® blog we are proud to share four publications with you:

Prognostic implications of QFR-derived residual disease patterns after stenting

Dr. N. Dai and co-authors under the supervision of Prof Junbo Ge, MD from Zhongshan hospital, Shanghai, China published a very interesting paper in JACC Interventions. They were interested in evaluating the clinical implications of residual disease patterns derived from the Quantitative Flow Ratio (QFR) pullback curve after PCI. In this retrospective study a total of 1607 vessels from 1335 patients were included.

From the QFR V2.0 post-PCI results, the following disease patterns were derived, being the PPG index and the dQFR/ds. Based on these patterns the patients were divided into 4 groups:  predominant focal/diffuse (PPG) and with/without major gradients (dQFR/ds). Clinical outcome was the 2-year VOCO, which was lowest (1.4%) in the group with predominant focal and without major gradient, and the highest (8.5%) in the group with diffuse disease and with major gradients. The authors conclude that objective analysis of post-PCI pullbacks can identify those with increased risk of VOCO, and who may benefit from additional interventions, which is superior to visual interpretations.

For further read: J Am Coll Cardiol Intv 2022; 15: 1624-1634;

Diagnostic agreement of QFR with FFR in Latin-American population

In this publication Dr. M. Echavarŕia-Pinto from the Hospital General ISSSTE in Santiago de Querétaro in Mexico and co-authors tested the diagnostic accuracy of the QFR in a Latin-American population. This is new evidence as most of the QFR clinical evidence is on European and Asian populations. They carried out a retrospective study in a single centre in 66 patients and 90 vessels with intermediate severity (average % diameter stenosis 46.6% and median FFR=0.83) to assess the diagnostic accuracy of the Quantitative Flow Ratio against wire-based Fractional Flow Reserve.

The correlation of both the fixed-QFR as well as the contrast-QFR was strong. For the contrast-QFR they found a sensitivity of 85.2%, a specificity of 80.6% and an area-under-the-curve of 0.92. The authors concluded that the QFR was strongly associated with the FFR.

For further read: Int J Cardiovasc Img 2022; 38: 1423-1430;

Interested in Medis QFR ®?

Easily request a demo of our innovative software solution

QFR to predict long-term coronary artery bypass patency

Dr. C. Dowling and colleagues from the Monash Cardiovascular Research Centre in Melbourne, Australia under the supervision of Dr. Dennis Wong published a paper in the Int. J. Cardiovascular Imaging on the above topic.

This is a small prospective study on 22 patients with left main coronary artery disease who were undergoing CABG; a total of 65 vessels were included in the analysis. At a medium FU of 3.6 years, 12 grafts were occluded. The Quantitative Flow Ratio demonstrated a discriminatory power to predict graft occlusion (AuC=0.70). The risk of graft occlusion was higher in vessels with a QFR > 0.80. The conclusion is that QFR may predict long-term graft patency in patients undergoing CABG.

For further read: Int J Cardiovasc Img 2022;

Two-year Outcomes of the FAVOR III China Trial; QFR favorable status confirmed after two years.

Dr. Lei Song from Fuwai hospital, Bejing, China and many co-authors under the supervision of Dr. Greg Stone, presented these 2-year FU data at the TCT 2022 in Boston, and the results are accepted for publication in JACC. This is the 2-year FU of the FAVOR III China trial, in which eligible patients were randomized to a QFR-guided strategy or a standard angiography-guided strategy.

Among the 3825 randomized participants, the 2-year MACE occurred in 8.5% in the QFR-guided group and in 12.5% in the angiography-guided group, a difference of 32% in favor of the QFR-guided group. The benefits were most pronounced among patients in whom QFR assessment altered the planned revascularization strategy.

For further read: Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: Two-Year Outcomes of the FAVOR III China Trial

Share this article on:


Interested in Medis QFR ®?

Easily request a demo of our innovative software solution

Sign up for our newsletter

Subscribe now to find out more about our solutions, latest publications and future releases.

By providing your information and continuing, you agree to Medis’ Terms of Use and Privacy Policy *

About the author

Hans Reiber image CSO of Medis - QFR

Prof. Hans Reiber

CSO of Medis Medical Imaging

Hans is co-founder and former CEO of Medis. He is also founder of the Division of Image Processing (LKEB), initially at the Thoraxcenter in Rotterdam and later at the Leiden University Medical Center (LUMC). He is emeritus professor for cardiovascular imaging both at the LUMC and the Interuniversity Cardiology Institute of the Netherlands (ICIN) and member of the Royal Netherlands Academy of Arts and Sciences (KNAW). Hans’ ambition has always been to bring innovative image-based quantitation applications into the hands of the clinicians and clinical researchers worldwide. Hans now serves as Chief Scientific Officer, heading Applied Research and is the primary point-of-contact for internal and external clinical research trials.